The predicted momentum of CAR T cell therapies has not fully materialized mainly arising from the inherent complexity of CAR T cell products, which results in a highly complex development process and, in turn, a slow speed-to-market. For example, there are many logistical challenges, including coordinating the variety of specialist scientists and the large number of reagents and consumable products required at different stages of production.
There are also numerous technical challenges related to accurately defining the product itself and establishing a robust and consistent process to manufacture the product at scale. To overcome these challenges, there are three main areas that should be prioritized during process development: equipment, reagents, and analytics. It is particularly important to consider these at the earliest stage possible, to help avoid late-stage protocol changes that can lead to costly delays.
In this paper we help you fully understanding the impact of optimizing these areas and how to identify the most appropriate options and strategies to achieve optimization.